BlueDot and Clarivate Partner to Strengthen the Resilience of Organizations, Through Heightened Disease Intelligence
BlueDot Inc., a global leader in infections disease intelligence, announced its partnership with Clarivate Plc, a global leader in providing trusted information and insights to accelerate the pace of innovation. Now, customers of Clarivate can access BlueDot’s innovative technology rooted in artificial intelligence (AI) and machine-learning to support in making educated, time-sensitive decisions in the face of biothreats.
BlueDot alerted organizations of the threatening emergence of COVID-19 nine days before the World Health Organization, and correctly predicted the spread of Zika into Florida, U.S. six months before it occurred. Since 2020, BlueDot has expanded its datasets and modelling to address the changing trends in endemic disease.
“As global epidemics emerge with greater frequency and severity, this partnership unlocks another step forward in building greater resiliency around the world”, stated Dr. Kamran Khan, Founder and CEO, BlueDot. “We must all play a role to prevent the spread of disease and are proud to partner with Clarivate to empower organizations to provide the actionable insights needed to do that.”
“Clarivate is committed to providing valuable, actionable intelligence to organizations of all types, ensuring more efficient preparation for future infectious disease outbreaks and the development of therapeutics for patients,” shared Gavin Coney, VP, Global Head of Partnerships, Clarivate. “With BlueDot leading the frontier of infectious disease detection and assessment to help prevent and address the spread of disease, the partnership will enable life sciences customers to benefit from in-depth, unparalleled analysis and customer-focused alerts and forecasts.”
Through Clarivate, organizations can access BlueDot’s infectious disease alerts and risk assessments, in addition to a wide variety of datasets, analysis, and modelling. Spanning both emerging and seasonal diseases, BlueDot alerts users to new emerging or active diseases and provides the analysis needed to determine how to respond.
[To share your insights with us, please write to email@example.com]